Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I StudyJung Min Lee, Elise C. Kohn, Tony W. Ho et al.|Journal of Clinical Oncology|2017Cited by 241
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analysesAlexandra S. Zimmer, Jung Min Lee, E. Hitt Nichols et al.|Journal for ImmunoTherapy of Cancer|2019Cited by 112
Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's CancerJung Min Lee, Elise C. Kohn, Cody J. Peer et al.|Clinical Cancer Research|2016Cited by 59
A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safetyJohn L. Hays, Elise C. Kohn, Geoff Kim et al.|Molecular and Clinical Oncology|2013Cited by 36
Feasibility and safety of sequential research‐related tumor core biopsies in clinical trialsJung Min Lee, Elise C. Kohn, John L. Hays et al.|Cancer|2012Cited by 33